GlassScriptPhysician profile
Sydney Krisa
NPI 1073258265
$2,978.70
in general payments reported to CMS, 2019-2025
8 companies · $194 in 2025
The $194 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,511 · 2024: $274 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,609 · Travel and Lodging: $1,274 · Entertainment: $95.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,608.96 |
| Travel and Lodging | $1,274.46 |
| Entertainment | $95.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valley Contax, INC. | $2,337.06 | 2023 | |
| Bausch & Lomb Americas INC. | $245.12 | 2024-2025 | Infuse |
| Coopervision INC. | $143.61 | 2023-2025 | Onefit Contact Lens, Misight Contact Lens |
| Tarsus Pharmaceuticals, INC. | $116.33 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $52.11 | 2023 | Cequa |
| Johnson & Johnson Vision Care, INC. | $47.91 | 2024-2025 | |
| Biotissue Holdings INC. | $18.91 | 2024 | |
| Alcon Vision LLC | $17.65 | 2024 | Precision 1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sydney Krisa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.